Literature DB >> 16420075

QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study.

Paul Mackin1, Allan H Young.   

Abstract

BACKGROUND: Antipsychotic drugs have been associated with prolongation of the QTc interval on the electrocardiogram, and QTc prolongation is, in turn, associated with an increased risk of cardiac arrhythmias and sudden death. Antipsychotic polypharmacy has been implicated in reduced survival, possibly secondary to cardiotoxic effects of antipsychotic medication. Abnormalities of glucose homeostasis, which may be more common in individuals with major mood disorders and schizophrenia, also affect the QTc interval.
METHOD: We performed detailed assessment of metabolic parameters in 103 psychiatric out-patients, from across the diagnostic spectrum, who had been taking antipsychotic medication (typical, atypical, or a combination thereof) for a minimum of 6 months. We measured the QTc interval in a subset of these patients (N = 65).
RESULTS: Only 2 patients (3%) had a prolonged QTc interval. There was a statistical trend (p = .08) toward a lower QTc interval in patients receiving antipsychotic polypharmacy. QTc interval was associated with age (p = .04) but not with any metabolic parameter.
CONCLUSION: QTc prolongation in this population is uncommon. There was a significant association between increasing age and QTc interval, but cardiac repolarization was not related to any metabolic parameter. Further large prospective studies of similar patients are needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16420075     DOI: 10.4088/jcp.v66n1107

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

2.  The QTc interval and its dispersion in patients receiving two atypical antipsychotics.

Authors:  Christoph U Correll; Anne M Frederickson; Vicki Figen; Elizabeth J Ginn-Scott; Rudy A Pantaleon Moya; John M Kane; Peter Manu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-20       Impact factor: 5.270

Review 3.  Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review.

Authors:  Hiroyoshi Takeuchi; Takefumi Suzuki; Gary Remington; Hiroyuki Uchida
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

4.  Electrocardiographic monitoring for new prescriptions of quetiapine co-prescribed with acetylcholinesterase inhibitors or memantine from 2005 to 2009. A population study on community-dwelling older people in Italy.

Authors:  Claudio Bilotta; Carlotta Franchi; Alessandro Nobili; Paola Nicolini; Codjo Djignefa Djade; Mauro Tettamanti; Luca Pasina; Ida Fortino; Angela Bortolotti; Luca Merlino; Carlo Vergani
Journal:  Eur J Clin Pharmacol       Date:  2014-09-20       Impact factor: 2.953

5.  Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics.

Authors:  Fu De Yang; Xiang Qun Wang; Xiu Ping Liu; Ke Xin Zhao; Wei Hong Fu; Xue Ru Hao; Xing Li Zhang; Guo Shu Huang; Sheng Cai Qu; Jing Shen Bai; Xu Feng Huang; Thomas R Kosten; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2011-02-09       Impact factor: 4.530

6.  Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety?

Authors:  Ronald Pies
Journal:  Psychiatry (Edgmont)       Date:  2009-06

7.  Electrocardiographic abnormalities as potential contributors to premature mortality in patients with mental illness in a psychiatric day treatment program.

Authors:  Mark Linzer; Karen C Baker; Sara Poplau; Ellen Coffey; Gautam Shroff; Inna Baum; Patrick Yoder; Pamela Clifford
Journal:  Prim Care Companion CNS Disord       Date:  2013-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.